CrossAssetDataThe Company File
···
TENX

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Chapel Hill, NC. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $0 thousand and a loss of $53 million (its filed statements).

Pre-revenue company Pharmaceutical Preparations Chapel Hill, NC filings since 1996 3 of 9 filed, 6 estimated
Ask the desk about TENX → Compare TENX with IMMX → Price chart on TradingView ↗ Full EDGAR file ↗ Watch TENX →

Sector peers: IMMXCTORIBIOBRNS

5.0/10headline grade
vs its business-model standard
3.1/10past 4.8/10present 6.5/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.0 out of ten, 3 of 9 metrics filed and 6 estimated: past 3.1 out of ten, present 4.8 out of ten, future 6.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 3.5 out of ten. 10 warning events since 2017; the latest 2024-01-12. 35th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 325 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Shareholder treatment (past): 0.1 out of ten. CrossAssetData estimate 0.1/10, confidence 35 of 100 (one part). 1st percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.3 out of ten. ROE -54%: lost 54¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar. 53rd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 5.2 out of ten. CrossAssetData estimate 5.2/10, confidence 20 of 100 (family median). 50th percentile among 314 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Leadership (present): 3.8 out of ten. bottom 38% of 315 in its family for leadership; chief executive since 2021. 38th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 9.4 out of ten. CrossAssetData estimate 9.4/10, confidence 35 of 100 (one part). 94th percentile among 479 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Growth drivers (future): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 308 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
  • Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.

The filing record

Newest annual report: Form 10-K filed 2026-03-10 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-07-31 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-07-31 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-09. Filings on record since 1996. Read from EDGAR 2026-10-12.

Who runs it

Giordano, Christopher Thomas (CEO); Staab, Thomas R II (Chief Financial Officer); Mcgauley, Thomas (Interim CFO); Rich, Stuart (Chief Medical Officer); Doogan, Declan (director); Almenoff, June Sherie (director); Davidson, Michael H. (director); Hunter, Robyn (director); Proehl, Gerald T (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.